Comprehensive Study Guide on Lipids and Lipoprotein Metabolism

General Properties and Overview of Lipids

• Definition: Lipids are a chemically diverse group of organic compounds defined primarily by their physical characteristic of insolubility in water and solubility in nonpolar organic solvents such as ether or chloroform.

• Chemical Structure: Primarily composed of carbon-hydrogen ($C-H$) bonds.

• Physical Property: Possess a lower specific gravity than water, allowing them to float on aqueous solutions.

• Primary Biological Functions:

  • Storage form of metabolic energy.
  • Key structural elements of biological cell membranes.
  • Active role as electron carriers in metabolic pathways.
  • Functional role as enzyme cofactors.

• Major Representative Categories: Triglycerides, Cholesterol, and Phospholipids.

Classification of Lipids

• Simple Lipids: Esters of fatty acids with various alcohols.

  • Fats
  • Oils
  • Waxes

• Complex Lipids: Esters of fatty acids containing groups in addition to an alcohol and a fatty acid.

  • Phospholipids
  • Glycolipids
  • Lipoproteins
  • Sulfolipids
  • Aminolipids

• Precursor and Derived Lipids: Compounds derived from simple or complex lipids by hydrolysis or metabolic transformation.

  • Fatty acids
  • Glycerol
  • Steroids
  • Ketone bodies
  • Hormones
  • Fat-soluble vitamins
  • Micronutrients

Fatty Acids

• Structure: Consist of simple linear chains of carbon-hydrogen ($C-H$) bonds terminating in a carboxyl group ($-COOH$).

• Plasma Concentration: Only a small fraction exists in plasma in an unesterified or free fatty acid (FFA) state; free fatty acids in plasma are bound to albumin.

• Storage and Association: The majority of fatty acids are esterified as components of triglycerides or phospholipids.

• Metabolic Function: Can be converted into intermediate metabolites utilized for gluconeogenesis.

• Classification by Carbon Chain Length:

  • Short-Chain Fatty Acids: Contain $C_2 - C_6$ carbon atoms. Absorbed directly across the intestinal mucosa into the bloodstream and transported straight to the liver via the hepatic portal vein.
  • Medium-Chain Fatty Acids: Contain $C_8 - C_{14}$ carbon atoms. Absorbed directly into the bloodstream and delivered via the hepatic portal vein.
  • Long-Chain Fatty Acids: Contain at least $C_{16}$ carbon atoms. Re-esterified upon absorption and packaged into chylomicrons to be transported through the lymphatic system before entering systemic circulation.
  • Very Long-Chain Fatty Acids: Contain at least $C_{22}$ carbon atoms.

• Classification by Degree of Saturation:

  • Saturated Fatty Acids: Contain no double bonds in the hydrocarbon chain. The carbon chain is fully saturated with hydrogen atoms, meaning all carbon-carbon bonds are single bonds ($C-C$).
  • Unsaturated Fatty Acids: Contain at least one double bond ($C=C$) within the hydrocarbon chain.

• Classification by Number of Double Bonds:

  • Monounsaturated Fatty Acids: Contain exactly one double bond in the hydrocarbon chain.
  • Polyunsaturated Fatty Acids: Contain two or more double bonds in the hydrocarbon chain.

Triglycerides

• Nomenclature: Commonly referred to as "Neutral Fat" or simply "Fats".

• Chemical Structure: Composed of three fatty acid molecules esterified to a single glycerol backbone via ester bonds.

• Physical Properties: Extremely hydrophobic and completely insoluble in water.

• Physiological Importance:

  • Serves as the primary storage lipid in human tissue, optimized for energy reserves.
  • Constitutes $95\%$ of all tissue storage fat.
  • Forms the predominant class of glyceryl esters detected in human blood plasma.

• Enzymatic and Hormonal Regulation of Breakdown:

  • Lipoprotein Lipase (LPL)
  • Epinephrine
  • Cortisol

• Metabolic Advantages of Triglycerides as Fuel Sources:

  • The carbon atoms in fatty acids are more reduced than those in carbohydrates or sugars, yielding significantly more energy per gram upon oxidation.
  • Triglycerides are completely hydrophobic and unhydrated, meaning organisms carrying fat reserves do not bear the extra body weight associated with hydration water required by carbohydrates.

• Laboratory Assessment and Reference Ranges:

  • Specimen Type: Serum or Plasma.
  • Patient Preparation: Requires a strict fasting period of $12 - 14\text{ hours}$.
  • Clinical Cut-off Levels:
  • Normal: $< 150\,mg/dL$
  • Borderline High: $150 - 199\,mg/dL$
  • High: $200 - 499\,mg/dL$
  • Very High: $> 500\,mg/dL$

• Chemical Analytical Methods:

  • Van Handel & Zilversmit (Colorimetric Method):
  • Extraction of serum lipids is performed using Folch's reagent (a chloroform-ethanol mixture).
  • Phospholipids are removed by adding an adsorbent material such as zeolite, alumina, or florisil.
  • Triglycerides undergo saponification with alcoholic $\text{KOH}$, hydrolyzing triacylglycerols (TAG) into free glycerol and fatty acids.
  • Glycerol is oxidized with periodic acid to produce formaldehyde.
  • Formaldehyde is reacted with a sulfuric acid ($\text{H}_2\text{SO}_4$) solution of chromotropic acid to form a blue-colored compound.
  • Absorbance of the blue derivative is measured spectrophotometrically at $570\,nm$
  • Hantzsch Condensation (Fluorometric Method):
  • Formaldehyde obtained from glycerol oxidation is reacted with diacetyl-acetone and ammonium ions ($\text{NH}_3$).
  • The condensation reaction produces $3,5\text{-diacetyl-}1,4\text{-dihydrolutidine}$, a yellow fluorescent compound with maximum absorbance at $412\,nm$
  • The fluorometric lutidine derivative formation is well suited for automated clinical analyzers.
  • Reference Methods:
  • Standard Reference Method: Modified Van Handel Zilversmit.
  • Modern Definitive Reference Method: Gas Chromatography / Mass Spectrometry (GC-MS).

• Enzymatic Method (Glycerol Kinase Cascade):

  • $\text{Triglycerides} + 3\text{H}_2\text{O} \xrightarrow{\text{Lipase}} \text{Glycerol} + 3\text{Fatty Acids}$
  • $\text{Glycerol} + \text{ATP} \xrightarrow{\text{Glycerol Kinase}} \text{Glycerol-3-Phosphate} + \text{ADP}$
  • $\text{Glycerol-3-Phosphate} + \text{NAD}^+ \xrightarrow{\text{Glycerophosphate Dehydrogenase}} \text{Dihydroxyacetone Phosphate} + \text{NADH} + \text{H}^+$
  • $\text{NADH} + \text{Tetrazolium Dye} \xrightarrow{\text{Diaphorase}} \text{Formazan} + \text{NAD}^+$

Cholesterol

• Chemical Nomenclature: $3\text{-hydroxy-}5,6\text{-cholestene}$.

• Chemical Structure: An unsaturated steroid alcohol consisting of a tetracyclic sterane ring nucleus (4 fused carbon rings) with a single carbon-hydrogen side chain, containing a total of 27 carbon atoms.

• Amphipathic Nature: Displays both hydrophilic and hydrophobic properties due to a polar hydroxyl group ($-OH$) located at the A-ring position 3, attached to an otherwise nonpolar steroid nucleus.

• Clinical Significance: Frequently measured as part of clinical risk assessments for Atherosclerosis, Myocardial Infarction, and Coronary Arterial Occlusions.

• Circulating Forms in Plasma:

  • Cholesteryl Esters: Account for $60\% - 70\%$ of total plasma cholesterol (esterified with long-chain fatty acids at the hydroxyl group).
  • Free Cholesterol: Accounts for $30\% - 40\%$ of total plasma cholesterol.

• Laboratory Assessment of Cholesterol:
  • Specimen Type: Plasma or Serum. Specimens that are hemolyzed, icteric, or contaminated with water must be avoided.
  • Fasting Requirement: Fasting is not mandatory for Total Cholesterol determination; accurate measurements can be obtained from non-fasting blood samples.
  • Chemical Reference Method (Abell, Levy, and Brodie Method):
  • Hydrolysis: A $0.5\,mL$ sample is placed in $20\,g/L$ alcoholic $\text{KOH}$ and hydrolyzed at $50^\circ\text{C}$ for $1\text{ hour}$.
  • Extraction: Hydrolysate is extracted using hexane via vigorous shaking at $25^\circ\text{C}$ for $15\text{ minutes}$.
  • Color Reaction: Extracted free cholesterol is reacted with the Liebermann-Burchard reagent.
  • Absorbance Measurement: Color intensity measured at $620\,nm$
  • Liebermann-Burchard Color Reaction:
  • A solution of cholesterol in acetic anhydride treated with concentrated sulfuric acid produces a characteristically changing display of colors progressing from red to violet, and ultimately to blue-green.
  • Enzymatic Method:
  • Allows accurate direct quantification without requiring prior organic solvent extraction.
  • $\text{Cholesteryl Ester} + \text{H}_2\text{O} \xrightarrow{\text{Cholesteryl Ester Hydrolase}} \text{Cholesterol} + \text{Fatty Acid}$
  • $\text{Cholesterol} + \text{O}_2 \xrightarrow{\text{Cholesterol Oxidase}} \text{Cholest-4-en-3-one} + \text{H}_2\text{O}_2$
  • $\text{H}_2\text{O}_2 + \text{Dye precursor} \xrightarrow{\text{Peroxidase}} \text{Quinoneimine Dye} + 2\text{H}_2\text{O}\ (\text{measured at } 500\,nm)$

Phospholipids

• Origin and Structure: Synthesized from phosphatidic acid. Structure resembles a triglyceride, except it features only two esterified fatty acids at the glycerol backbone, with the third position bound to a phosphate head group.

• Physical Properties: Strongly amphipathic molecule with polar heads and nonpolar fatty acid tails.

• Biological Function: Forms the fundamental structural lipid bilayer component of cellular membranes.

• Clinical Testing Status: Not routinely analyzed in clinical laboratories due to two major factors:

  1. Phospholipid quantitation generally provides minimal additional diagnostic value during evaluations of dyslipoproteinemia.
  2. Plasma phospholipid concentration does not fluctuate as significantly or predictably as cholesterol and triglycerides in response to various disease states.

Lipoproteins

• Definition: Spherical macromolecular complexes containing lipids and specialized proteins termed "apolipoproteins" or "apoproteins".

• Structural Organization:

  • Nonpolar Hydrophobic Core: Packed with nonpolar neutral lipids, including triglycerides and cholesteryl esters.
  • Amphipathic Shell: Surface monolayer consisting of single-layer phospholipids, unesterified free cholesterol, and apolipoproteins.

• Physiological Purpose: Transport hydrophobic triglycerides and cholesterol through the aqueous environment of blood plasma, keeping lipids solubilized.

• Major Lipoprotein Classes:

  • Chylomicrons:

  • Composition: Composed of $90\%$ Triglycerides, $1\% - 2\%$ Proteins, plus small amounts of phospholipids and cholesterol.

  • Physical Characteristics: Represents the largest particle size and lowest density of all lipoproteins.

  • Site of Origin: Synthesized in intestinal mucosal cells.

  • Physiological Role: Primary transport vehicle for exogenous (dietary) triglycerides from the gut to peripheral tissues.

  • Associated Apolipoproteins: Apo B-48, Apo C, Apo E.          

  • Very Low-Density Lipoprotein (VLDL):

  • Electrophoretic Synonym: "Pre-beta lipoprotein".

  • Composition: Composed of $65\%$ Triglycerides, $16\%$ Cholesteryl Esters, $5\% - 10\%$ Proteins, and phospholipids.

  • Site of Origin: Synthesized in the liver.

  • Physiological Role: Primary transport vehicle for endogenously synthesized hepatic triglycerides.

  • Associated Apolipoproteins: Apo B-100, Apo C, Apo E.          

  • High-Density Lipoprotein (HDL):

  • Electrophoretic Synonym: "Alpha-lipoprotein" (commonly referred to as "Good Cholesterol").

  • Composition: Composed of $45\% - 50\%$ Protein, $30\%$ Phospholipids, $20\%$ Cholesteryl Esters, and $2\% - 7\%$ Triglycerides.

  • Physical Characteristics: Smallest particle diameter and highest density among all lipoprotein classes.

  • Associated Apolipoproteins: Apo A-I, Apo A-II, Apo C.

  • Clinical Quantification Method: Quantified in supernatant after selective chemical precipitation of Apo B-containing lipoproteins using reagents such as dextran sulfate or polyethylene glycol (PEG).

  • Low-Density Lipoprotein (LDL):

  • Electrophoretic Synonym: "Beta-lipoprotein".

  • Composition: Composed of $50\%$ Cholesteryl Esters, $24\% - 28\%$ Phospholipids, $18\%$ Protein, and $6\% - 8\%$ Free Cholesterol.

  • Associated Apolipoproteins: Apo B-100, Apo E.

  • Clinical Quantification Method: Routinely calculated indirectly using the Friedewald equation.

The Friedewald Equation and Lipid Profile

• Friedewald Formula: Used to calculate Low-Density Lipoprotein Cholesterol (LDL-C):   $\text{LDL-C} = \text{TC} - \text{HDL-C} - \left(\frac{\text{TG}}{5}\right)$(Where $\text{TC}$ is Total Cholesterol, $\text{HDL-C}$ is High-Density Lipoprotein Cholesterol, $\text{TG}$ is total Triglycerides, and $\frac{\text{TG}}{5}$ estimates Very Low-Density Lipoprotein Cholesterol, $\text{VLDL-C}$. Valid only when $\text{TG} < 400\,mg/dL$).

• Standard Clinical Lipid Profile Panel: A diagnostic grouping of blood tests used to evaluate patient lipid homeostasis and estimate risk for cardiovascular diseases:

  • Triglycerides
  • Total Cholesterol
  • High-Density Lipoprotein Cholesterol (HDL-C)
  • Low-Density Lipoprotein Cholesterol (LDL-C)
  • (Optionally includes calculated VLDL-C)

Lipid Absorption and Metabolic Pathways

• Intestinal Lipid Absorption Processes:

  1. During luminal digestion, pancreatic lipase converts complex dietary lipids into simpler polar compounds.
  2. Amphipathic lipids assemble with bile salts to form polymolecular aggregations called "micelles". These micelles migrate across microvillus membranes of intestinal mucosal epithelial cells.
  3. After cellular uptake, fatty acids and monoglycerides are re-esterified back into triglycerides and cholesteryl esters inside mucosal cells, then assembled into chylomicrons along with Apo B-48.
  4. Absorbed short-chain fatty acids bypass chylomicron assembly, passing directly into portal circulation bound to serum albumin for direct hepatic delivery.

• Exogenous Lipid Pathway:

  1. Nascent chylomicrons enter intestinal lacteals, traveling through lymphatic vessels to join systemic venous circulation via the thoracic duct.
  2. Circulating chylomicrons contact capillary endothelial luminal surfaces in muscle and adipose tissue, binding to endothelial proteoglycans.
  3. Endothelial Lipoprotein Lipase (LPL) hydrolyzes core triglycerides transported inside the chylomicrons.
  4. Free fatty acids released during LPL breakdown enter adjacent cells to be oxidized for cellular energy or re-esterified for tissue lipid storage.
  5. Excess surface phospholipids and apolipoproteins are transferred off the shrinking particle onto HDL, shrinking the chylomicron into a chylomicron remnant.
  6. Chylomicron remnants bind hepatic remnant receptors and undergo receptor-mediated endocytosis into liver lysosomes, releasing internal free cholesterol and fatty acids.

• Endogenous Lipid Pathway:

  • Function: Transports liver-synthesized lipids outward to peripheral cells for systemic metabolic energy needs.
  1. Hepatically assembled VLDL particles are secreted into systemic circulation.
  2. Endothelial LPL hydrolyzes VLDL triglycerides, converting VLDL into VLDL remnants, Intermediate-Density Lipoproteins (IDL), and ultimately Low-Density Lipoproteins (LDL).
  3. LDL particles deliver cholesterol payloads to peripheral cells via binding interaction with specific cell-surface LDL receptors.
  4. Triglycerides released from LDL are broken down into free fatty acids and glycerol for peripheral energy consumption or tissue storage.
  5. Free cholesterol released into cells is used for membrane biogenesis, while extra cellular cholesterol is esterified by intracellular Acyl-CoA:Cholesterol Acyltransferase (ACAT) for cellular storage.
  6. Remaining LDL particles return to the liver and are cleared by hepatic LDL receptors.

• Reverse Cholesterol Transport Pathway:

  • Function: Removes toxic excess cellular cholesterol from peripheral cell membranes and returns it to the liver for clearance into bile.
  1. Cellular cholesterol exits peripheral cells via an aqueous diffusion pathway.
  2. Active cholesterol efflux occurs through ATP-Binding Cassette cell membrane transporters ABCA-1 and ABCG-1 onto HDL acceptors for transport back to hepatic tissue.

Fate of Lipids: Storage and Mobilization

• Lipid Storage Mechanisms:

  • Surplus systemic lipids are sequestered inside specialized cells called adipocytes in the form of stored lipid droplets.
  • Droplet Core Structure: Concentrated sterol esters and neutral triglycerides.
  • Droplet Boundary Structure: Encased by a monolayer of phospholipids.
  • Droplet Surface Regulation: The outer surface layer is coated with structural proteins called Perilipins, which form a physical barrier preventing unregulated enzyme access or premature lipid mobilization.

• Lipid Mobilization Cascade:

  1. Epinephrine, Glucagon, or Cortisol signals the metabolic demand for energy, binding adipocyte surface receptors to activate membrane-bound Adenylyl Cyclase.
  2. Activated Adenylyl Cyclase synthesizes cyclic adenosine monophosphate (cAMP).
  3. Elevated cAMP activates Cyclic-AMP dependent Protein Kinase A (PKA).
  4. Active PKA phosphorylates structural Perilipin molecules on the lipid droplet surface.
  5. Phosphorylated Perilipin rearranges, allowing cytosolic Hormone-Sensitive Lipase (HSL) to dock onto the lipid droplet surface and begin hydrolyzing stored triglycerides.
  6. HSL can also be directly phosphorylated by PKA to dramatically increase its catalytic breakdown rate.
  7. Released free fatty acids diffuse into the vascular system, binding tightly to plasma albumin to be carried through the circulation to target peripheral tissues.
  8. Concurrently released glycerol is converted by hepatic Glycerol Kinase through phosphorylation into glycerol 3-phosphate.

Fate of Lipids: Utilization

• Fatty Acid Oxidation - Mitochondrial Entry:

  • Short-chain and medium-chain fatty acids ($\le 12$ carbons) cross outer and inner mitochondrial membranes directly without transport proteins.
  • Long-chain fatty acids ($\ge 14$ carbons) cannot cross directly and must be processed through the Carnitine Shuttle System:
  • Acyl-CoA Synthetase catalyzes thioester linkage formation between the carboxyl carbon of the fatty acid and the thiol group of Coenzyme A, converting ATP to AMP and producing high-energy Fatty Acyl-CoA.
  • Carnitine Acyltransferase I (CAT-I / CPT-I), situated on the outer mitochondrial membrane, transfers the fatty acyl group from CoA onto carnitine to form Fatty Acyl-Carnitine.
  • Fatty Acyl-Carnitine translocates across the inner mitochondrial membrane via the acyl-carnitine/carnitine transporter.
  • Carnitine Acyltransferase II (CAT-II / CPT-II), located on the inner matrix surface, transfers the fatty acyl group back onto intramitochondrial Coenzyme A, regenerating Fatty Acyl-CoA inside the mitochondrial matrix and releasing free carnitine.

• Fatty Acid Oxidation - Beta Oxidation Pathway:

  1. Fatty Acyl-CoA undergoes repetitive oxidative cleavage cycles, removing two-carbon units per pass from the carboxyl end to produce Acetyl-CoA molecules.
  2. Generated acetyl groups of Acetyl-CoA enter the Citric Acid Cycle (TCA cycle), undergoing oxidation to $\text{CO}_2$
  3. Dehydrogenation steps during $\beta$-oxidation and the TCA cycle yield reduced electron carriers $\text{NADH}$ and $\text{FADH}_2$, which transfer electrons to the electron transport chain to generate ATP via oxidative phosphorylation.

• Citric Acid Cycle Integration:

• Oxidation of Odd-Carbon Chain Fatty Acids:

  • Odd-numbered fatty acids proceed through standard $\beta$-oxidation cycles until the final cycle.
  • The final cleavage pass hydrolyzes a 5-carbon fatty acyl-CoA intermediate, yielding one 2-carbon Acetyl-CoA and one 3-carbon Propionyl-CoA.
  • Propionyl-CoA undergoes enzymatic conversion to Succinyl-CoA, which directly enters the Citric Acid Cycle.

• Ketogenesis:

  • High rates of hepatic fatty acid breakdown increase mitochondrial Acetyl-CoA levels beyond the capacity of the citric acid cycle.
  • Two Acetyl-CoA molecules condense to form Acetoacetate.
  • Acetoacetate is converted into Acetone or $\beta\text{-hydroxybutyrate}$.
  • Circulating ketone bodies diffuse into extrahepatic tissues, where $\beta\text{-hydroxybutyrate}$ is converted back into 2 Acetyl-CoA molecules to serve as fuel.

Biosynthesis of Lipids

1. Triglyceride Reformation: Free fatty acids and glycerol-3-phosphate (derived from excess carbohydrates) are re-esterified to form storage triglycerides.
2. Cholesterol Esterification: Unesterified free cholesterol is converted into hydrophobic cholesteryl esters by ACAT or LCAT enzymes.
3. Membrane Synthesis: Free fatty acids and unesterified cholesterol are directed into complex phospholipid synthesis pathways for membrane maintenance.
4. De Novo Fatty Acid Lipogenesis: Excess cytosolic Acetyl-CoA is converted into new long-chain fatty acids through the fatty acid synthase complex.

Clinical Pathologies: Atherosclerosis, Myocardial Infarction, and Obesity

• Atherosclerosis:
  • Definition: Chronic vascular disease characterized by progressive hardening and narrowing of arterial walls caused by lipid-rich atherosclerotic plaques lining the arterial intima.
  • Clinical Consequences: Major underlying etiology of cardiovascular diseases (CVD), ischemic heart attacks, and cerebrovascular strokes due to blood flow restriction.

• Pathophysiological Phases:

  1. Initiation Phase: Characterized by subendothelial deposition of atherogenic Apo B lipoproteins, proinflammatory vascular signals, and endothelial cell dysfunction.
  2. Progression Phase: Subendothelial accumulation of oxidized lipids, recruitment of monocyte-derived macrophages, and formation of lipid-engorged "foam cells". Vascular smooth muscle cells migrate from the media into the intima, synthesizing extracellular matrix to form fibrous plaques (fibroatheroma) or fibrocalcific plaques.
  3. Complication Phase: Growing plaques restrict luminal diameter, causing downstream ischemia. Plaque rupture exposes thrombogenic necrotic core material to blood, triggering rapid platelet aggregation, fibrin polymerization, and acute thrombus formation.

• Clinical Symptoms: Early or mild atherosclerosis is usually asymptomatic. Symptoms manifest when luminal narrowing restricts perfusion to target tissues:

  • Angina pectoris (chest pain)

  • Shortness of breath (dyspnea)

  • Systemic fatigue

  • Numbness, coldness, or weakness in upper or lower extremities

  • Acute Myocardial Infarction (AMI):

• Pathophysiology: Severe ischemic necrosis of heart muscle resulting from sudden occlusion of coronary arterial blood flow, starving myocardial tissues of oxygen.

• Primary Cause: Acute rupture of an unstable atherosclerotic plaque within coronary arteries followed by occlusive thrombus formation.

  • Obesity:

• Definition: Complex metabolic and nutritional disease defined by abnormal or excessive accumulation of body fat mass resulting from a chronic imbalance between total energy intake and total energy expenditure.

• Etiology: Caused by interactions between genetic susceptibility factors and acquired environmental/lifestyle changes.

• Epidemiology: Major global public health concern; childhood obesity strongly predicts adult obesity and associated metabolic syndrome risks.